& Haematology Haematology is a complex and challenging area of medicine. At Roche, finding innovative solutions for those affected by diseases of the blood is not only a priority, it's in our blood. Challenge Haematology covers everything from cancers of the blood to bleeding disorders, tke haemophilia, and ‘complement system ciseases, such as paroxysmal nocturnal haemoglobinuria. Though cverse in nature, Whats common across mary of thase d'seases isthe serious impact they can have on survival and {quality of fe, Blood cancers alone ar the fourth most comman cause of cancer-related death worldwide; the three most common types of blood cancer being myeloma, leukaemia and lymphoma. Despite considerable progress over the years, many patients stl have limited treatment options ‘avaliable to them. To tackle these challenges, we have embarked on ourneys of collaboration with ‘academic institutions, regulatory authorities and ather companies in the hove of entitying trends or insights from the vast amounts of elnical data across blood diseases, which n turn could lead to future innovations.Focus (ur commitment extends yard develsing Innovative thaapies, to plying a wir ein improving patient's quality of ife, We are exoloring the best ways to deliver innovations to patients as quickly and cffectively as possible, hich includes evolving and improving how our clinical tials are designed ana how our therapies are administered. We ar also looking at new ways to measure treatment success ‘through tho use of aternative clinical endpoints. ‘We continue to invest in bringing innovative treatment options ro people with ciseases of the blood, as ‘our teams strive to continually deliver transformational change for patients and the physicians who treat them Cases in detail LBEF 4 aElOm©, Solutions Lymphoma > Haemophilia A > Weare aiming to transform standards of care for each and every patient with We are working closely wth the haemophila community to transform the way Ymphoma by developing therapies that can help them to achieve long lasting haemophilais treated and managed, and provide consistent and predictable responses with minialimpact on their day-to-day ie. access to treatment for those who need most. Stories of Haematology Seemore stories >What is paroxysmal nocturnal haemoglobinuria (PNH)? December 08, 2022 Rare within rare: women with haemophilia, ‘April 14,2022 More focus areas Haemophitia A in infants December 07,2022 allfocus areas >Diabetes > Cardiometabolic diseases > _ Infectious diseases > Discover more Partnering with Pharma > ‘At Roche Pharma Partnering we are passionate about sc¥ence: no mater where it comes from. Trough partnerships we can bua better future together with medicines that make areal cifference to patients. Innovation Clinical trials ° Ctincal trials are essential to determine whether new drugs or clagnostics are safe and effective when used to diagnose or reat people.